CICC Capital Closes $229 Million Fund for China Biologic Investments

CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. In November of last year, CICC teamed up with AstraZeneca to raise up to $1 billion over several years to back China life science startups. Shortly after, CICC announced its own fund, which has now closed slightly above its $213 million goal. Some of the money will go to companies making COVID-19 vaccines and therapies. More details.... Stock Symbol: (NYSE: AZN) Share this with colleagues: // //